Pulmonary Function Testing for Neonatal Respiratory Disorders
(PUFFOR Trial)
Trial Summary
What is the purpose of this trial?
This trial uses a new device to measure lung function in newborns by sending gentle airwaves into their lungs while they breathe normally. It targets term and preterm infants, especially those with lung diseases, because traditional methods are difficult and often require sedation. This method is easier and safer for measuring lung function in newborns.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What data supports the effectiveness of the treatment Non-invasive forced airway oscillometry for neonatal respiratory disorders?
Research shows that techniques like impulse oscillometry, which are part of the treatment, are effective in measuring lung function in children with conditions like asthma and cystic fibrosis. These methods are non-invasive, require minimal cooperation, and are sensitive in detecting changes in small airways, making them suitable for young children and potentially effective for neonatal respiratory disorders.12345
Is pulmonary function testing using oscillometry safe for humans?
Pulmonary function testing using oscillometry, which includes techniques like forced oscillation and impulse oscillometry, is generally considered safe for humans. It is non-invasive, requires minimal patient cooperation, and is suitable for young children and those unable to perform traditional lung function tests.12467
How is non-invasive forced airway oscillometry different from other treatments for neonatal respiratory disorders?
Non-invasive forced airway oscillometry is unique because it requires minimal patient cooperation and is more sensitive in detecting changes in small airways compared to traditional pulmonary function tests. This makes it particularly useful for infants who cannot perform standard tests due to their age or condition.1891011
Research Team
Namasivayam Ambalavanan, MD
Principal Investigator
University of Alabama at Birmingham
Eligibility Criteria
This trial is for infants born at or after 22 weeks of gestation who are off ventilators for at least 12 hours. It's open to those whose parents or guardians consent, but not to babies with terminal illnesses, neuromuscular conditions affecting breathing, major malformations, or if there's a decision to limit support.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Non-invasive forced airway oscillometry (Procedure)
Non-invasive forced airway oscillometry is already approved in Canada for the following indications:
- Assessment of lung function in preterm infants
- Diagnosis of respiratory diseases such as bronchopulmonary dysplasia
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor